Presentations

The Evolving Treatment Landscape for CSCC

2024
ADA Meeting
Squamous Cell Carcinoma

Reflections on the evolving treatment landscape for CSCC
Oct 24, 2024
David M. Miller

Optimizing Melanoma Outcomes in Rural and Underserved Communities: Adapting to Evolving Treatment Paradigms

2024
Oncology Congress
Melanoma
CME

We summarize the clinical evidence for the efficacy and safety of new and emerging therapeutic options and treatment strategies for cutaneous melanoma
Sep 28, 2024
David M. Miller

Update in the Management of Advanced Cutaneous Squamous Cell Carcinoma

2024
CME
CSCC
Las Vegas Dermatology

This live program will explore key clinical practice insights for patients with advanced CSCC
Sep 21, 2024
David M. Miller

Update in the Management of Non-Resectable Melanoma

2024
CME
Melanoma
Las Vegas Dermatology

This live program will explore key clinical practice insights for patients with non-resectable melanoma
Sep 21, 2024
David M. Miller

Shifting the Approach to Nonmelanoma Skin Cancer in Dermatology

2024
CME
CSCC
BCC
Las Vegas Dermatology

This live program will explore key clinical practice insights for patients with advanced Non-Melanoma Skin Cancer
Sep 20, 2024
David M. Miller

Advanced Non-Melanoma Skin Cancer in Veterans: Incorporating Advances in Immune Checkpoint Inhibitors to Optimize Outcomes

2024
CME
CSCC
BCC

This program will explore key clinical practice insights for patients with advanced Non-Melanoma Skin Cancer
Sep 19, 2024
David M. Miller

A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies

2024
CME
BCC

This program will explore key clinical practice insights for patients with advanced basal cell carcinoma
Sep 4, 2024
David M. Miller, Todd Schlessinger

Incorporating Multidisciplinary Care and Immunotherapy to Achieve Optimal Outcomes in Patients With Nonmelanoma Skin Cancers

2024
CME
Holovision
CSCC
BCC

This HoloVision program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Aug 9, 2024
David M. Miller

Should Ipilimumab Be the New “Standard” for Refractory MCC?

2024
Merkel Cell Carcinoma
Ipilimumab
Ipi/Nivo

We discuss the role of Ipilimumab in anti-PD1 refractory MCC
May 3, 2024
David M. Miller

Updates in Merkel Cell Carcinoma

2024
AAD Meeting
Merkel Cell Carcinoma

Pearls on the current concepts in diagnosis and management of MCC
Mar 10, 2024
David M. Miller

Peri-operative Management of CSCC

2024
AAD Meeting
CSCC

Pearls on peri-omanagement of high-risk resectable CSCC
Mar 9, 2024
David M. Miller

The Prognostic Value of the MCPyV Serum Antibody Test

2024
Merkel Cell Carcinoma

We discuss results from a dual-institution observational study
Mar 8, 2024
David M. Miller

Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Nonmelanoma Skin Cancer

2024
CME
TeleECHO

This live virtual program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Jan 19, 2024
David M. Miller

Melanoma Update

2024
Melanoma
ODAC
ODAC Dermatology, Aesthetic & Surgical Conference “Medical & Surgical Dermatology Topics”
Jan 14, 2024
David M. Miller

Merkel Cell Carcinoma- Current Concepts in Diagnosis and Management

2024
MCC
ODAC
ODAC Dermatology, Aesthetic & Surgical Conference “Non-Melanoma Skin Cancer Update”
Jan 13, 2024
David M. Miller

Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Nonmelanoma Skin Cancer

2024
CME
TeleECHO

This live virtual program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Jan 5, 2024
David M. Miller

Reshaping the Treatment Landscape in the Department of Veteran Affairs: Immunotherapy in Nonmelanoma Skin Cancer

2024
CME
TeleECHO

This live virtual program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Jan 3, 2024
David M. Miller

Interdisciplinary Management of Advanced Cutaneous Malignancy

2023
CME
Las Vegas Dermatology
Melanoma

Management Pearls for the Peri-Operative Management of Melanoma
Nov 3, 2023

Putting the Patient First. The Value of Personalized Medicine for Nonmelanoma Skin Cancers

2023
CME
CSCC
BCC
ESMO

Management Pearls for Advanced NMSC
Oct 22, 2023

Management of Cutaneous Melanoma

2023
Harvard Plastic Surgery Residency

Management of Cutaneous Melanoma
Oct 11, 2023
David M. Miller

Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management

2023
Pennsylvania Academy of Dermatology

Current concepts in diagnosis and management of MCC
Sep 22, 2023
David M. Miller

Nicotinamide For Skin Cancer After Transplant

2023
AAADV

Discuss the evidende behind the use of nicotinamide for skin cancer prevention
Sep 14, 2023
David M. Miller

Prognostic Significance of Initial AMERK Serostatus

2023
SoCO Research Forum
MCC

We discuss results from a dual-institution observational study
Aug 18, 2023
David M. Miller

Immunotherapeutic Strategies in Skin Cancer

2023
Harvard Dermatology

Primer on Immunotherapeutic Strategies in Skin Cancer
Aug 2, 2023
David M. Miller

StoryboardR - An R Package and Shiny Application Designed to Visualize Real-World Data From Clinical Patient Registries

2023
R/Medicine
Clinical Informatics

We present an overview of the StoryboardR package
Jun 8, 2023

The Emerging Standard of Care - Immunotherapy in Non-Melanoma Skin Cancer

2023
CME
CSCC
BCC

This live program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Jun 5, 2023
David M. Miller

Mission - Impossible to Possible Using Immunotherapy for the Treatment of Nonmelanoma Skin Cancers

2023
CME
CSCC
BCC

Management Pearls for Advanced CSCC
Jun 4, 2023

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
May 25, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
May 22, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
May 10, 2023
David M. Miller

Complementary Therapeutic Approaches: Mohs Micrographic Surgery and Immunotherapy in Non-Melanoma Skin Cancer

2023
CME
NMSC

This live hybrid program will explore key clinical practice insights for patients with advanced and high-risk resectable NMSC
May 6, 2023
David M. Miller, Sailesh Konda

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
May 1, 2023
David M. Miller

mGODS - Monoclonal Gammopathies Of Dermatological Significance

2023
Harvard Dermatology

Pearls for working up monclonal gammopathies in setting of dermatological disease
Apr 21, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Apr 12, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Apr 10, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Apr 6, 2023
David M. Miller

Integrating the Latest Evidence on Management of Basal Cell Carcinoma

2023
Oncology Congress
BCC

We discuss implementation of evidence-based strategies for reducing disparities in basal cell carcinoma (BCC) care in rural and underserved settings
Apr 1, 2023
David M. Miller

Integrating Novel Treatment Approaches for Cutaneous Squamous Cell Carcinoma

2023
Oncology Congress
CSCC

We summarize the clinical evidence for the efficacy and safety of new and emerging therapeutic options and treatment strategies for cutaneous squamous cell carcinoma
Apr 1, 2023
David M. Miller

ICARUS

2023
SoCO Research Forum
CSCC

We discuss a trial concept for high-risk CSCC
Mar 31, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Mar 30, 2023
David M. Miller

Exploring Neoadjuvant Immunotherapies for Surgically Resectable Cutaneous Squamous Cell Carcinoma

2023
CME
CSCC

This live program will explore key clinical practice insights for patients with advanced cutaneous squamous cell carcinoma
Mar 19, 2023
David M. Miller, Vishal A. Patel

Updates in Merkel Cell Carcinoma

2023
AAD Meeting
Merkel Cell Carcinoma

Pearls on the current concepts in diagnosis and management of MCC
Mar 18, 2023
David M. Miller

Management of High Risk Uncommon Cutaneous Neoplasms

2023
AAD Meeting
Merkel Cell Carcinoma

Pearls on the current concepts in diagnosis and management of uncommon cutaneous neoplasms
Mar 17, 2023
David M. Miller

Management of Operable Advanced NMSC

2023
AAD Meeting
BCC
CSCC

Pearls on the current concepts in diagnosis and management of operable non-melanoma skin cancer
Mar 17, 2023
David M. Miller

How do we implement systemic therapy to reduce recurrence of high-risk melanomas: from neoadjuvant to adjuvant therapy?

2023
AAD Meeting
Melanoma

Pearls on the current concepts in peri-operative management of high-risk melanoma
Mar 17, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Mar 13, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Mar 9, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Mar 2, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Feb 23, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Feb 15, 2023
David M. Miller

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Feb 15, 2023
David M. Miller

Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced melanoma
Feb 13, 2023
David M. Miller

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2023
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Feb 8, 2023
David M. Miller

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2023
CME
TeleECHO
Med Learning Group TeleECHO. Event URL
Feb 6, 2023
David M. Miller

New Systemic Therapies for the Treatment of Advanced Non-Melanoma Skin Cancers: Which of Your Patients May Benefit?

2023
CME
BCC
CSCC

We review new systemic therapies for the Treatment of Advanced NMSCs
Jan 23, 2023
David M. Miller, Vishal A. Patel

The Essential Roles of Dermatologists in Managing Patients with Advanced Basal Cell Carcinoma

2022
CME

This gamification-based activity highlights how to diagnose, treat, and/or manage patients with advanced basal cell carcinoma.
Nov 22, 2022
David M. Miller

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2022
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Nov 21, 2022
David M. Miller

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2022
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Nov 18, 2022
David M. Miller

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2022
CME
TeleECHO

This live virtual TeleECHO program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Nov 17, 2022
David M. Miller

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2022
CME
TeleECHO
Med Learning Group TeleECHO. Event URL
Nov 9, 2022
David M. Miller

Cutaneous Malignancies: How Would You Manage This Patient?

2022
CME
Innovations in Derm

Interactive session with a series of skin cancer experts discussing management of complex skin cancer patients.
Nov 4, 2022
David M. Miller, Douglas Grossman, Steven Wang, Vishal A. Patel

Prognostic Gene Expression Profiling for Cutaneous Squamous Cell Carcinoma: Does it Add to Staging

2022
CME
Innovations in Derm

We discuss the current data regarding prognostic gene expression profiling in CSCC
Nov 4, 2022
David M. Miller

Cases in Basal Cell Carcinoma: Fostering Interdisciplinary Care

2022
CME
Innovations in Derm

We discuss cases in the management of advanced BCC.
Nov 4, 2022
David M. Miller, Kavita Sarin, Vishal A. Patel

Optimizing the Management of Patients With Advanced Non-Melanoma Skin Cancers in Community-Based Dermatology, Oncology, and Dermato-Oncology Practices

2022
CME
TeleECHO
Med Learning Group TeleECHO. Event URL
Oct 26, 2022
David M. Miller

Practical Management Pearls for Immunotherapy for the Treatment of Nonmelanoma Skin Cancer

2022

We discuss perals from the recent SITC practice guidelines on NMSC
Oct 3, 2022
Isaac Brownell, David M. Miller, Sunandana Chandra, Emily S. Ruiz

Immunotherapeutic Strategies in Skin Cancer

2022
Harvard Dermatology

Primer on Immunotherapeutic Strategies in Skin Cancer
Aug 17, 2022
David M. Miller

The Clinician Investigator - A Buttress Against Type III Error or a Contributor to the Crisis in Reproducibility?

2022
COIG Research Meeting

In this two part series, we discuss elements of the crisis in reproducibility in clinical research.
Jul 11, 2022
David M. Miller

Dealing with Non-Responders to Systemic Therapy for Basal Cell Carcinoma

2022
Dialogues in Derm

In this podcase, we discuss pearls on the management of advanced BCC
Jun 13, 2022
David M. Miller

mGODS - Monoclonal Gammopathies Of Dermatological Significance

2022
Harvard Dermatology

Pearls for working up monclonal gammopathies in setting of dermatological disease
May 6, 2022
David M. Miller

Merkel Cell Carcinoma- Current Concepts in Diagnosis and Management

2022
CME
Innovations in Derm
Merkel Cell Carcinoma

Pearls in the management of Merkel Cell Carcinoma
Apr 30, 2022
David M. Miller

Basal Cell Carcinoma: How to Effectively Manage Your Patients

2022
CME
Innovations in Derm

Pearls in the management of Basal Cell Carcinoma
Apr 30, 2022
David M. Miller

Diagnostic Yield of Staging Brain MRI in Merkel Cell Carcinoma

2022

Real world evaluation of initial brain MRI in MCC
Apr 26, 2022
David M. Miller

Real-world assessment of ipi-nivo in anti-PD-(L)-1 refractory Merkel Cell Carcinoma

2022

Real world evaluation of ipilimumab/nivolumab in PD-1/PDL-1 refractory MCC
Apr 25, 2022
Sophia-Shalhout

Seeing Nonmelanoma Skin Cancers Through a New Lens - The Role and Place of Immunotherapy

2022

Pearls on the current concepts in diagnosis and management of NMSC
Apr 22, 2022
Axel Hauschild, David M. Miller, Vishal Patel

Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management

2022
AAD Meeting
Merkel Cell Carcinoma

Pearls on the current concepts in diagnosis and management of MCC
Mar 28, 2022
David M. Miller

Real-world assessment of ipi-nivo in anti-PD-(L)-1 refractory Merkel Cell Carcinoma

2022

Real world evaluation of ipilimumab/nivolumab in PD-1/PDL-1 refractory MCC
Mar 25, 2022
Sophia-Shalhout

Peer Insights on the Management of Patients With Cutaneous Squamous Cell Carcinoma

2022
CME

Management Pearls for Advanced CSCC
Mar 25, 2022
Kevin Emerick, David M. Miller

Peer Insights on the Management of Patients With Cutaneous Squamous Cell Carcinoma

2022
CME

Management Pearls for Advanced CSCC
Mar 18, 2022
Kevin Emerick, David M. Miller

Management of Advanced Cutaneous Melanoma

2022
Melanoma

Pearls for the work up and management of cutaneous melanoma
Mar 10, 2022
David M. Miller

Non Melanoma Skin Cancer Immunotherapies and the Role of Dermatology Clinicians

2022
CME

Management Pearls for Advanced NMSC
Mar 1, 2022
Vishal Patel, Krista Rubin, David M. Miller

Immunotherapy in Advanced NMSC - Treatment Selection and Collaborative Care

2022
CME

Pearls for the Management of Advanced NMSC
Feb 14, 2022
Vishal Patel, Krista Rubin, David M. Miller

Generating an Anti-Tumor Response - Immune System Activation for the Treatment of Advanced/Metastatic BCC and cSCC

2022
CME
BCC
CSCC

Pearls for the Management of Advanced NMSC
Jan 14, 2022
David M. Miller

Generating an Anti-Tumor Response - Immune System Activation for the Treatment of Advanced/Metastatic BCC and cSCC

2022
CME
BCC
CSCC

Pearls for the Management of Advanced NMSC
Jan 7, 2022
David M. Miller

Generating an Anti-Tumor Response - Immune System Activation for the Treatment of Advanced/Metastatic BCC and cSCC

2021
CME
CSCC
BCC

This live virtual Grand Rounds program will explore key clinical practice insights for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas
Dec 14, 2021
David M. Miller

Clinical and Translational Research in Cutaneous Oncology

2021

Pearls for a career in CT research in skin cancer
Dec 3, 2021
David M. Miller

Management of Cutaneous Melanoma

2021
Melanoma
Harvard Dermatology

In this lecture to the Harvard Dermatology residents, we provide pearls for the management of cutaneous melanoma
Dec 3, 2021
David M. Miller

Accelerate Health

2021
Merkel Cell Carcinoma

At the 2021 CEO Roundtable on Cancer Annual Conference we provide an update on the PDS MCC patient registry
Nov 17, 2021
David M. Miller, Kerry Reynolds, Bill Louv

Generating an Anti-Tumor Response - Immune System Activation for the Treatment of Advanced/Metastatic BCC and cSCC

2021
CME

Pearls for the Management of Advanced NMSC
Nov 11, 2021
David M. Miller

The MCC Patient Registry - From Promise to Prototype to Patient

2021
Merkel Cell Carcinoma
Grand Rounds

For this MGH Dermatology Grand Rounds we present an overview of the PDS MCC patient registry
Nov 2, 2021
David M. Miller

Generating an Anti-Tumor Response - Immune System Activation for the Treatment of Advanced/Metastatic BCC and cSCC

Pearls for the Management of Advanced NMSC
Oct 8, 2021
David M. Miller

Squamous Cell Carcinoma - Current Concepts in Management

2021
CSCC

In this lecture for the Nurse Practioners on the Medical Oncology Inpatient Service, we reivew pearls on the current concepts in management of SCC
Oct 4, 2021
David M. Miller

GENETEX - A GENomics Report TEXt Mining R Package to Capture Real-World Clinico-genomic Data

2021
R/Medicine
Clinical Informatics

We present an overview of the GENETEX package
Aug 26, 2021
David M. Miller, Sophia-Shalhout

Nonmelanoma Skin Cancers - Who Is in the Waiting Room

Pearls on the current concepts in diagnosis and management of NMSC
Aug 7, 2021
David M. Miller, Hari Nadiminti, Vishal Patel

Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management

2021
AAD Meeting
Merkel Cell Carcinoma

In this talk for the Summer AAD we review pearls on the current concepts in diagnosis and management of MCC.
Aug 7, 2021
David M. Miller

Diagnostic Yield of Staging Brain MRI in Merkel Cell Carcinoma

We discuss the utility of brain MRI for the initial staging of MCC
Jul 19, 2021
Farees Saqlain

Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management

2021
Merkel Cell Carcinoma

Pearls on the current concepts in diagnosis and management of MCC
Jun 11, 2021
David M. Miller

eLAB - a Large-Scale Laboratory Integration Informatics Pipeline for Clinical Research

May 17, 2021
Sophia-Shalhout

GENETEX - an NLP R Package for Text Mining Genomic Reports

May 7, 2021
David M. Miller

Immune Checkpoint Inhibitor for Cutaneous Squamous Cell Carcinoma

2021
CSCC

Pearls for the Management of Advanced CSCC
Apr 22, 2021
Kevin Emerick, Gina Jefferson, Miriam Lango, Matthew Witek, David M. Miller

An Innovative View of Advanced and Metastatic Basal Cell Carcinoma- Pathology, Epidemiology, and Treatment Option

Pearls for the Management of Advanced BCC
Mar 22, 2021
David M. Miller, Emily Ruiz

mGODS - Monoclonal Gammopathies Of Dermatological Significance

2021
Harvard Dermatology

Pearls for working up monclonal gammopathies in setting of dermatological disease
Mar 18, 2021
David M. Miller

MCC Patient Registry - Lessons Learned, Future Directions

Mar 11, 2021
David M. Miller

MCC Patient Registry - Lessons Learned on Data Capture

Feb 26, 2021
David M. Miller

Work Up and Management of Cutaneous Melanoma

2021
Melanoma

In this online lecture for the DC Resident Consortium, we provide pearls for the work up and management of cutaneous melanoma
Feb 25, 2021
David M. Miller

Project Data Sphere & MCC patient Registry- From Promise to Prototype to Patient

We provide updates and future directions of the PDS-GOBDA MCC Registry
Feb 23, 2021
David M. Miller

Developing Immunotherapy for Advanced Disease - Leveraging the Tumorigenesis of Basal Cell Skin Cancer – A Whiteboard View

Pearls for the Management of Advanced BCC
Jan 27, 2021
David M. Miller, Emily Ruiz

Project Data Sphere & MCC patient Registry- From Promise to Prototype to Patient

We provide updates and future directions of the PDS MCC Registry
Jan 22, 2021
David M. Miller

Squamous Cell Carcinoma - Work Up and Management

Pearls for the Work Up & Management of CSCC
Sep 9, 2020
David M. Miller

The Evolving Landscape of Regulatory Medicine in Cutaneous Oncology

Analysis of the changing regulatory environment in skin cancer
Sep 9, 2020
David M. Miller

Management of Cutaneous Melanoma

Pearls for the management of cutaneous melanoma
Aug 21, 2020
David M. Miller

The MCC Patient Registry - Updates and Future Directions

Aug 7, 2020
David M. Miller

Salt, Water, Urine, EAV

Pearls for the Evaluation of Hyponatremia
2020

Practical pearls to help evaluate hyponatremia
May 24, 2020
David M. Miller

Acid-Base Pearls Part 1

The Strong Ion Approach to Acid-Base Disorders

Pearls on how to approach Acid-Base issues commonly seen on inpatient medicine
May 23, 2020
David M. Miller

Pearls from the Cascade

Overview & Learning Objectives
May 22, 2020
David M. Miller

Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management

Overview & Learning Objectives
Apr 16, 2020
David M. Miller

Squamous Cell Carcinoma - Epidemiology, Pathophysiology, Work Up and Management

Overview & Learning Objectives
Feb 28, 2020
David M. Miller

Heme-Derm - Principles at the Intersection of Blood and Skin

We review overlapping principles of Dermatology and Hematology
Feb 28, 2020
David M. Miller

Merkel Cell Carcinoma - Current Concepts in Diagnosis and Management

We review current concepts in diagnosis and management for MCC
Feb 8, 2020
David M. Miller

The MCC Patient Registry - From Promise to Prototype to Patient

Jan 31, 2020
David M. Miller

MCC Patient Registry - Updates and Future Directions

Jan 29, 2020
David M. Miller

Skin Toxicities of Anti-Neoplastic Medications

Jan 27, 2020
David M. Miller

Melanoma - Pathogenesis, Clinical Features, Work Up & Management

We review key pearls in melanoma pathogenesis and management
Jan 23, 2020
David M. Miller

Therapeutic Updates in Melanoma - IO for Earlier Stage Disease

2020
Melanoma
ODAC
Jan 18, 2020
David M. Miller

Merkel Cell Carcinoma- Current Concepts in Diagnosis and Management

2020
MCC
ODAC
Jan 17, 2020
David M. Miller

The Evolving Landscape of Regulatory Medicine in Cutaneous Oncology

Dec 13, 2019
David M. Miller

Melanoma - Pathogenesis, Clinical Features, Diagnosis and Management

Dec 13, 2019
David M. Miller

Targeting the Hippo-YAP Pathway As a novel Therapeutic Approach in Cancer

Dec 12, 2019
Sophia-Shalhout

A Case of Bimodality Therapy for Merkel Cell Carcinoma

Dec 3, 2019
Farees Saqlain

Clinical Investigation in cSCC - Updates from ASCO and ESMO

Nov 19, 2019
David M. Miller

Project Data Sphere and Ongoing Multi-Institutional Database Efforts

2019
Merkel Cell Carcinoma

We present on the PDS MCC patient registry at the First International Symposium on Merkel Cell Carcinoma
Oct 21, 2019
David M. Miller

2019 ASCO IO Abstracts Review

Oct 7, 2019
David M. Miller

Work Up and Management of Non-Melanoma Skin Cancer

Aug 23, 2019
David M. Miller

Diagnosis and Initial Management of Melanoma

Aug 23, 2019
David M. Miller

MCC Patient Registry

Aug 20, 2019

Melanoma - Work Up and Management

Aug 2, 2019
David M. Miller

Melanoma - Epidemiology and Pathogenesis

Aug 1, 2019
David M. Miller

Merkel Cell Carcinoma Tumor Registry

Jun 18, 2019
David M. Miller

Approach to the Skin Biopsy

Jun 10, 2019
David M. Miller

Project Data Sphere & MCC patient Registry- From Promise to Prototype to Patient

Jun 2, 2019

Clinical and Translational Research in Cutaneous Oncology

May 20, 2019
David M. Miller

Cutaneous Oncology Board Preparation

May 20, 2019
David M. Miller

Regulatory Medicine in Cutaneous Oncology

May 7, 2019
David M. Miller

Merkel Cell Carcinoma

2019
Merkel Cell Carcinoma

In this lecture for the GWU School of Medicine Dermatology residents we provide a overview of the diagnosis and managment of Merkel Cell Carcinoma
Apr 18, 2019
David M. Miller

Regulatory Medicine in Cutaneous Oncology

Apr 2, 2019
David M. Miller

Neoadjuvant PD-1 Blockade in Resectable Melanoma

Mar 25, 2019
David M. Miller

Project Data Sphere & the MCC Patient Registry - From Promise to Prototype to Patient

2019
Merkel Cell Carcinoma

We present the concept of the PDS MCC patient registry at the annual Merkel Cell Carcinoma Interest Group Meeting
Mar 1, 2019
David M. Miller

Sezary Syndrome Part 2 - Diagnosis and Management

Feb 22, 2019
David M. Miller

Sezary Syndrome Part 1 - Pathogenesis and Clinical Features

Feb 15, 2019
David M. Miller

mGODS - Monoclonal Gammopathies Of Dermatological Significance

First described↩︎
Feb 8, 2019
David M. Miller

Sezary Syndrome

Jan 17, 2019
David M. Miller

mGODS - Monoclonal Gammopathies of Dermatological Signficance

(https://www.themillerlab.io/talk/harvard_derm_resident_mgods-01-31-17/)↩︎
Jan 17, 2019
David M. Miller

Reducing M&M in M&M - Strategies to improve Morbidity and Mortality in Melanoma and Merkel cell carcinoma

Dec 19, 2018
David M. Miller

FDA Action in Cutaneous Oncology

Overview of regulatory medicine in skin cancer
Nov 9, 2018
David M. Miller

Sezary Syndrome

Nov 9, 2018
David M. Miller

PDS MCC Tumor Registry

Oct 22, 2018
David M. Miller

FDA Action in Cutaneous Oncology

Oct 22, 2018

PAMPs, DAMPs and Dermatology

Aug 24, 2018
David M. Miller

TCRs, Tsubs and dHSRs - T-cell Immunity for the Dermatologist

Aug 24, 2018
David M. Miller

Introduction to Melanoma

Jul 31, 2018
David M. Miller

Merkel Cell Carcinoma - Updates in Diagnosis and Management

Jun 14, 2018
David M. Miller

Merkel Cell Carcinoma

May 18, 2018
David M. Miller

Introduction to Melanoma

May 18, 2018

The Biology of Cutaneous Oncology

May 18, 2018
David M. Miller

mGODS - Monoclonal Gammopathies of Dermatological Signficance

First described↩︎
May 18, 2018
David M. Miller

PAMPs DAMPs and Dermatology - Innate Immunity for the Dermatologist

May 8, 2018
David M. Miller

mGODS - Monoclonal Gammopathies Of Dermatological Significance

2019
Harvard Dermatology
First described↩︎
Dec 19, 2017
David M. Miller

No Claims No Gains - Why You Need to Know the Business Side of Medicine

Dec 14, 2017
David M. Miller, Xin Gao

Common Primary Care Dermatoses

Dec 8, 2017
David M. Miller

Sezary Syndrome

Nov 21, 2017
David M. Miller

Nivolumab as Adjuvant Therapy for Melanoma

Oct 31, 2017
David M. Miller

Common Primary Care Dermatoses

Oct 6, 2017
David M. Miller

Common Primary Care Dermatoses

Sep 22, 2017
David M. Miller

Introduction to Melanoma

Aug 15, 2017
David M. Miller

Sezary Syndrome

May 30, 2017
David M. Miller

Sezary Syndrome

May 24, 2017
David M. Miller

Avelumab for Patients with Merkel Cell Carcinoma

May 2, 2017
David M. Miller

mGODS - Monoclonal Gammopathies Of Dermatological Significance

2017
Harvard Dermatology
Jan 31, 2017
David M. Miller

Scratching the Surface of Acute Graft vs. Host Disease

Jun 10, 2016
David M. Miller

Approach to Purpura

Mar 25, 2016
David M. Miller

The Red Leg

Jan 29, 2016
David M. Miller

Mycosis Fungoides - Clinical Features, Diagnosis & Management

Jan 15, 2016
David M. Miller

Merkel Cell Carcinoma

Dec 3, 2015
David M. Miller

Cellulitis and Its Mimics

Nov 6, 2015
David M. Miller

Vesiculobullous Eruptions

Oct 9, 2015
David M. Miller

Common Primary Care Dermatoses

Jul 24, 2015
David M. Miller

A Case of Early-Onset Dementia

Jun 17, 2015
David M. Miller

A Patient with Fever and Rash

Jun 1, 2015
David M. Miller

A Painful Rash

Apr 15, 2015
David M. Miller

Melanoma

Mar 27, 2015
David M. Miller

Biology of Keratinocytes

Jan 28, 2015
David M. Miller

Emerging Therapies in Melanoma

Apr 16, 2014
David M. Miller

Environmental and Sports-Related Skin Diseases

Mar 5, 2014
David M. Miller

Overstimulated

Feb 19, 2014
David M. Miller

Immunology Review - T-Cell Immunity

Jan 5, 2014
David M. Miller

Progression After Failure

May 22, 2013
David M. Miller

Deep Impact

May 22, 2013
David M. Miller

Melanoma

Apr 26, 2013
David M. Miller

Environmental and Sports-Related Skin Diseases

Mar 20, 2013
David M. Miller

B-Cell Immunology for the Dermatologist

Aug 22, 2012
David M. Miller

T-Cell Immunology for the Dermatologist

Aug 15, 2012
David M. Miller

Biology of Keratinocytes

Aug 10, 2012
David M. Miller

Severe Scalp SCCs In a Heart Transplant Recipient

May 16, 2012
David M. Miller

Cutaneous B-Cell Lymphoma

Apr 25, 2012
David M. Miller

Melanoma

Apr 13, 2012
David M. Miller

Painful Papules

Jan 25, 2012
David M. Miller
No matching items